Amgen Inc (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Ticker
AMGN
Exchange
Nasdaq
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$250.07B
52-week range
$312.39 - $483.99

Valuation

Share price
$462.32 (close of Nov 16, 2026)
P/E (TTM)
26.60x
Price to book
17.42x
Price to free cash flow
26.10x
Enterprise value
$290.89B
Book value per share
$26.53

Price performance

PeriodChange
1 day-0.72%
5 days-0.63%
1 month+6.90%
3 months+11.35%
6 months+41.68%
Year to date+41.25%
1 year+37.29%
3 years+71.87%
5 years+125.09%
10 years+214.01%
All time+134,393.09%

Short interest

As of
Oct 30, 2026
Short % of float
2.33%
Shares short
12.59M
Days to cover
4.97
Change since prior report
-5.87%
Source
FINRA consolidated short interest

Members of Congress who disclosed AMGN trades

David Taylor · Marjorie Taylor Greene · Jefferson Shreve · Jared Moskowitz · Julia Letlow · Lisa McClain · Maria Elvira Salazar · Sheldon Whitehouse · Alan Armstrong · Cliff Bentz · Daniel Meuser · Emily Randall

And 4 others

Super investors holding AMGN

Ken Griffin (Citadel) · David Katz (Matrix Asset Advisors Inc) · Ray Dalio (Bridgewater Associates) · Dodge & Cox (Dodge & Cox Funds) · Mairs & Power (Mairs & Power Inc)

Profitability and growth

Return on equity
89.06%
Return on invested capital
12.35%
Return on assets
8.51%
Return on capital employed
13.95%
Gross margin
67.25%
Net margin
20.98%
EBITDA margin
38.77%
Revenue growth
9.95%
Net income growth
88.53%
Free cash flow growth
-22.07%

Cash flow and balance sheet

Free cash flow yield (TTM)
3.83%
Current ratio
1.48x
Net debt to EBITDA
2.25x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$36.75B
Cost of revenue
$12.04B
Gross profit
$24.71B
EBITDA
$14.25B
Net income
$7.71B
Earnings per share
$14.33
Research and development
$7.27B
Shares outstanding
538.00M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$36.75B$24.71B$7.71B$14.33
2024-12-31$33.42B$20.57B$4.09B$7.62
2023-12-31$28.19B$19.74B$6.72B$12.56
2022-12-31$26.32B$19.92B$6.55B$12.18
2021-12-31$25.98B$19.52B$5.89B$10.34
2020-12-31$25.42B$19.27B$7.26B$12.40
2019-12-31$23.36B$19.01B$7.84B$12.96
2018-12-31$23.75B$19.65B$8.39B$12.70
2017-12-31$22.85B$18.78B$1.98B$2.71
2016-12-31$22.99B$18.83B$7.72B$10.32

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3167.25%20.98%89.06%12.35%
2024-12-3161.53%12.24%69.59%10.21%
2023-12-3170.02%23.83%107.78%9.54%
2022-12-3175.66%24.89%178.97%20.59%
2021-12-3175.16%22.68%87.96%16.79%
2020-12-3175.77%28.57%77.20%19.30%
2019-12-3181.35%33.57%81.07%20.89%
2018-12-3182.73%35.35%67.15%19.63%
2017-12-3182.19%8.66%7.84%8.23%
2016-12-3181.90%33.59%25.85%12.96%

Cash and debt by year

Period endCashDebt
2025-12-31$9.13B$50.01B
2024-12-31$11.97B$56.55B
2023-12-31$10.94B$63.17B
2022-12-31$9.30B$37.35B
2021-12-31$8.04B$33.22B
2020-12-31$10.65B$32.90B
2019-12-31$8.91B$26.95B
2018-12-31$29.30B$29.51B
2017-12-31$41.68B$34.19B
2016-12-31$38.09B$30.19B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$8.10B$494.00M
2024-12-31$10.39B$530.00M
2023-12-31$7.36B$431.00M
2022-12-31$8.79B$401.00M
2021-12-31$8.38B$341.00M
2020-12-31$9.89B$330.00M
2019-12-31$8.53B$308.00M
2018-12-31$10.56B$311.00M
2017-12-31$10.51B$329.00M
2016-12-31$9.62B$311.00M

Dividend history

Most recent payment
Aug 21, 2026
Paid in the last twelve months
$9.94
Payment dateDividend per share
2026-08-21$2.52
2026-05-15$2.52
2026-02-13$2.52
2025-11-21$2.38
2025-08-22$2.38
2025-05-16$2.38
2025-02-14$2.38
2024-11-18$2.25

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-03Sep 2026$5.74
2026-08-04Jun 2026$5.60
2026-04-30Mar 2026$4.73
2026-02-03Dec 2025$4.76
2025-11-04Sep 2025$5.00
2025-08-05Jun 2025$5.26
2025-05-01Mar 2025$4.16
2025-02-04Dec 2024$5.03

Filings and sources

Company website
amgen.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Gilead Sciences, Inc. (GILD) · AstraZeneca plc (AZN) · Pfizer Inc (PFE) · Novartis AG (NVS) · Bristol Myers Squibb Co (BMY) · Merck & Co., Inc. (MRK) · Biogen Inc. (BIIB) · AbbVie Inc. (ABBV)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades